BioMarin Pharmaceutical (BMRN) Fundamentals 2026 — P/E 41.7x, Revenue Analysis | SniperIQ
BioMarin Pharmaceutical (BMRN) is a US-listed Healthcare company in Biotechnology with a market capitalization of
.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.Market Cap
P/E (TTM)41.7x
Net Margin8.3%
Revenue (FY25)
.2BFull research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is BioMarin Pharmaceutical's market cap?
BioMarin Pharmaceutical (BMRN) has a market capitalization of approximately
What is BioMarin Pharmaceutical's P/E ratio?
BioMarin Pharmaceutical's trailing twelve-month P/E ratio is 41.7x, with a price-to-book (P/B) of 1.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is BioMarin Pharmaceutical?
BioMarin Pharmaceutical runs a net profit margin of 8.3%, a gross margin of 75.9%, and an operating margin of 13.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does BioMarin Pharmaceutical generate?
BioMarin Pharmaceutical reported revenue of